What Researchers Did
Researchers investigated the effects of hyperbaric oxygen therapy (HBOT) on pancreatic β-cell function and hepatic gluconeogenesis in streptozotocin (STZ)-induced type-2 diabetic mice.
What They Found
Hyperbaric oxygen therapy (HBOT) significantly decreased fasting blood glucose, fasting insulin, and insulin resistance (HOMA-IR) in diabetic mice. It also improved glucose tolerance, insulin sensitivity, and pancreatic β-cell function, increasing insulin secretion and reducing β-cell apoptosis. Additionally, HBOT decreased hepatic gluconeogenesis by reducing key enzyme expression and modulated specific protein expressions in pancreatic and liver tissues.
What This Means for Canadian Patients
This research suggests that hyperbaric oxygen therapy (HBOT) could potentially offer a new approach to improve blood sugar control and pancreatic function for Canadian patients with type 2 diabetes. However, these findings are from an animal study and require extensive human clinical trials to determine safety and efficacy before clinical application.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or patients.
Study Limitations
A primary limitation of this study is that its findings are based on an animal model, which may not directly translate to human physiology and clinical outcomes.